First Analysis assumed coverage on shares of NeoGenomics Inc. (NASDAQ:NEO) in a research note issued to investors on Monday. The firm issued an overweight rating and a $11.00 target price on the stock.
Several other brokerages also recently issued reports on NEO. Craig Hallum reiterated a buy rating on shares of NeoGenomics in a report on Saturday, July 9th. Zacks Investment Research downgraded NeoGenomics from a buy rating to a hold rating in a report on Thursday, July 28th. BTIG Research downgraded NeoGenomics from a buy rating to a neutral rating in a report on Wednesday, July 27th. Benchmark Co. increased their price target on NeoGenomics from $10.00 to $12.00 and gave the company a buy rating in a report on Wednesday, July 27th. Finally, Raymond James Financial Inc. began coverage on NeoGenomics in a report on Thursday, September 8th. They issued an outperform rating and a $10.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $10.41.
NeoGenomics (NASDAQ:NEO) opened at 8.08 on Monday. NeoGenomics has a 12-month low of $5.49 and a 12-month high of $9.54. The stock’s market capitalization is $629.38 million. The company has a 50-day moving average price of $8.11 and a 200-day moving average price of $8.10.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, July 26th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.01. NeoGenomics had a positive return on equity of 3.18% and a negative net margin of 3.76%. The firm earned $63.10 million during the quarter, compared to the consensus estimate of $61.07 million. During the same period in the prior year, the firm earned $0.01 EPS. The firm’s quarterly revenue was up 159.0% compared to the same quarter last year. On average, equities research analysts forecast that NeoGenomics will post $0.13 earnings per share for the current year.
In other news, insider Maher Albitar sold 370,000 shares of the stock in a transaction dated Friday, August 19th. The shares were sold at an average price of $8.23, for a total transaction of $3,045,100.00. Following the transaction, the insider now owns 263,492 shares of the company’s stock, valued at $2,168,539.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 12.20% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. State Street Corp boosted its position in shares of NeoGenomics by 0.9% in the first quarter. State Street Corp now owns 777,559 shares of the company’s stock valued at $5,241,000 after buying an additional 7,266 shares during the last quarter. Falcon Point Capital LLC raised its stake in NeoGenomics by 12.5% in the second quarter. Falcon Point Capital LLC now owns 209,538 shares of the company’s stock valued at $1,685,000 after buying an additional 23,216 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its stake in NeoGenomics by 14,127.6% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 142,276 shares of the company’s stock valued at $959,000 after buying an additional 141,276 shares during the period. Fox Run Management L.L.C. acquired a new stake in NeoGenomics during the second quarter valued at $171,000. Finally, Geode Capital Management LLC raised its stake in NeoGenomics by 3.8% in the first quarter. Geode Capital Management LLC now owns 355,158 shares of the company’s stock valued at $2,393,000 after buying an additional 13,052 shares during the period. 77.20% of the stock is currently owned by institutional investors and hedge funds.
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.